Vical Vaccine Adjuvant Boosts Immune Response to Influenza Vaccine
Posted on: Monday, 16 October 2006, 12:01 CDT
Vical has reported data from a study showing that an adjuvant originally developed to boost the immune response to its DNA vaccines also boosts the immune response to a conventional influenza vaccine.
Results from the studies suggest that the company's patented vaccine adjuvant known as Vaxfectin has the potential to be used as a dose-sparing agent with conventional flu vaccines against seasonal or pandemic flu strains. The company is developing a Vaxfectin-formulated DNA vaccine designed to protect against emerging strains of flu virus that have the potential to cause a pandemic.
In the study Vaxfectin-formulated vaccines yielded significantly higher immune response than unformulated vaccines at the same dose.
Vical's lead Vaxfectin-formulated, three-component DNA vaccine candidate against avian flu provided 100% protection in mice and ferrets against lethal challenges with a highly virulent H5N1 virus.
Vaxfectin formulations have demonstrated good tolerability and adjuvant activity in multiple animal models.
Source: Datamonitor
Related Articles
- Expert Panel Concludes There is No Evidence Surgical Masks Protect Against Flu
- New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
- Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses
- Exercise May Enhance Flu Vaccine Response
- Latest Data Confirm GlaxoSmithKline's Proprietary Adjuvant System For Cervarix(TM) Induces a Stronger and More Sustained Immune Response Than a Conventional Adjuvant Formulation
- Researchers Boost Newborns' Vaccine Responses
- Red Wine Found to Be Also Good Against Flu: Report
- HK Public Urged to Observe Good Hygiene Against Flu
- Pregnant Women Often Not Vaccinated Against Flu
- Agency: Vigilance Against Flu Helped U.S.
 |
 |
User Comments (0)
RSS Feeds